Hubbry Logo
Collagenous colitisCollagenous colitisMain
Open search
Collagenous colitis
Community hub
Collagenous colitis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Collagenous colitis
Collagenous colitis
Collagenous colitis
View on Wikipedia
from Wikipedia
Collagenous colitis
Micrograph of collagenous colitis. H&E stain.
SpecialtyGastroenterology

Collagenous colitis is an inflammatory condition of the colon. Together with the related condition lymphocytic colitis, it is a subtype of microscopic colitis, which is characterized by inflammation that specifically affects the colon (i.e. colitis), and a clinical presentation that involves watery diarrhea but a lack of rectal bleeding. Microscopic colitis does not usually cause macroscopic changes to the colon that allow a visual diagnosis during colonoscopy, instead causing microscopic changes that can be detected through histopathological examination of colonic biopsies. The nature of these microscopic changes is what differentiates collagenous from lymphocytic colitis, with the characteristic finding in collagenous colitis being depositions of collagen in the connective tissue between the colonic glands.[1] Collagenous colitis, and microscopic colitis as a whole, is sometimes considered to be an inflammatory bowel disease (IBD) along with Crohn's disease and ulcerative colitis. However, little is known about the etiology of microscopic colitis, and so the degree of similarity to the inflammatory bowel diseases is uncertain.[1][2]

Although cases are known to occur in all age groups, the disease is most frequently diagnosed in late middle aged or elderly people, with the average person being diagnosed in their 60s. Women are more frequently affected than men, with different studies finding female-male incidence ratios of between 3 and 8. Epidemiological studies have found large increases in diagnosed cases of microscopic colitis, of which collagenous colitis cases are a majority, over the past few decades, with cases of microscopic colitis now outnumbering those of Crohn's disease and ulcerative colitis at least in some regions.[3][4]

Signs and symptoms

[edit]

In general, microscopic colitis causes chronic watery diarrhea with increased stool frequency. Some patients report nocturnal diarrhea, abdominal pain, bowel urgency, fecal incontinence, fatigue and weight loss. In severe cases, symptoms may include dehydration and electrolyte imbalances.[5] Patients report a significantly diminished quality of life.[1][6] In a retrospective study specifically on collagenous colitis patients, all studied patients experienced chronic diarrhea, 42% experienced weight loss, 41% experienced abdominal pain, 27% of the patients experienced nocturnal diarrhea, while 14% experienced fatigue and 8% experienced meteorism. The median patient had 6 stools per day. Among the patients who experienced weight loss and whose magnitude of weight loss was recorded, the median lost weight was 6 kg.[7]

Causes

[edit]

The cause of collagenous colitis is unknown. A connection with autoimmune disorders such as celiac disease is suspected, as up to 40% of patients with collagenous colitis have an autoimmune disease. Use of nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs) and beta blockers also appear to increase the risk of collagenous colitis, but the cause of this is not known.[1]

Diagnosis

[edit]

On colonoscopy, the mucosa of the colon typically looks normal, but biopsies of affected tissue usually show deposition of collagen in the lamina propria, which is the area of connective tissue between colonic glands. Radiological tests, such as a barium enema are also typically normal.[6]

Treatment

[edit]

First line treatment for collagenous colitis is the use of budesonide, a steroid that works locally in the colon and is highly cleared by first pass effect. Other medications that can be used include the following:[1][6]

Pilot-scale studies have shown some evidence of possible benefit for both Boswellia serrata extract and specific strains of probiotics in the treatment of collagenous colitis, although larger sample sizes are needed to confirm the results.[8][9][10]

Epidemiology

[edit]

One epidemiological study reported previous incidence rates of collagenous colitis found in the literature as ranging from 0.6 cases per 100,000 person-years (based on French data from 1987–1992) to 5.2 per 100,000 person-years (from an Icelandic study based on data from 1995–1999), while the authors themselves found an incidence rate of 3.1 per 100,000 person-years in Olmsted County, Minnesota across the period 1985–2001. Based only on the subset of the data from 1998–2001, however, the authors found a higher rate of 7.1 per 100,000 person-years, an incidence rate which exceeded those of Crohn's disease and ulcerative colitis.[11] The previously mentioned Icelandic study also found increasing rates through the studied period, with the incidence rate in Iceland increasing from 2.2 in 1995 to 8.3 in 1999.[12] Women appear to be more frequently affected by collagenous colitis than men, with the Icelandic study finding a female–male ratio of 7.9 in diagnosed cases and the Olmsted County study finding a female–male ratio of 4.4.[11][12]

An updated study on microscopic colitis in Olmsted County published in 2022 and based on data from between 2011 and 2019 found an incidence rate for collagenous colitis of 9.9 cases per 100,000 person-years, a prevalence of 100.1 per 100,000 persons and a female–male ratio of 4.7. Unlike in the previous study on data from 1995–1999, the rate of collagenous colitis in Olmsted County was found to have remained stable between 2011 and 2019.[3] Another study on rates of microscopic colitis in Denmark between 2001 and 2016 found an overall incidence rate for collagenous colitis of 12.2 per 100,000 person-years, a prevalence of 116.7 per 100,000 persons and a female–male ratio of 3.1. Like the 1995–1999 Olmsted County study and the 1995–1999 Icelandic study, this Danish study found a heavy increase in rates of collagenous colitis and microscopic colitis overall during the studied period, with the incidence rates in 2001 and 2016 for microscopic colitis found to be, respectively, 2.3 and 24.3 cases per 100,000 person-years. However, the incidence rates of collagenous colitis in this Danish data peaked in 2011 with a rate of 19.6 cases per 100,000 person-years, and rates appeared to be stable between 2012 and 2016. The average age at diagnosis was found to be 67, and the highest incidence rate was found among patients over the age of 80. The strong increase in the case rates of microscopic colitis (with collagenous colitis making up 59% of these cases) throughout the study period meant that by 2016, microscopic colitis had a greater incidence rate in Denmark than did Crohn's disease and ulcerative colitis. The authors suggest an increase in the use of colonoscopies as a possible cause of the observed change in microscopic colitis diagnoses over time.[4]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Collagenous colitis

View on Grokipedia
from Grokipedia
Collagenous colitis is a subtype of , a chronic inflammatory condition of the colon characterized by the deposition of a thickened subepithelial band greater than 10 micrometers in thickness, leading to watery, non-bloody despite a grossly normal appearance of the colonic mucosa on . This disorder primarily affects the colon and is distinguished from other forms of by its microscopic pathology, with no increased risk of colon cancer. The hallmark symptom of collagenous colitis is chronic, non-bloody, watery , often occurring 4 to 9 times per day and sometimes accompanied by fecal urgency, incontinence, abdominal , , , , or . Symptoms typically fluctuate in severity and may mimic or other causes of , with extraintestinal manifestations such as joint pain occurring in some cases. Epidemiologically, it predominantly affects individuals over 50 years old, with a peak around age 65, and shows a marked female predominance (3:1 ratio compared to males); incidence rates range from 2 to 10.8 per 100,000 population, higher in and . The exact of collagenous colitis remains unclear but is thought to involve a multifactorial interplay of immune dysregulation, (such as the HLA-DR3-DQ2 ), and environmental triggers. Potential triggers include certain medications like nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors, and selective serotonin reuptake inhibitors; ; autoimmune disorders such as celiac disease, , or ; and possibly genetic factors or alterations in the colonic epithelial barrier leading to increased deposition via transforming growth factor-beta-1 (TGF-β1). It differs from lymphocytic colitis, the other main subtype of , primarily in its histopathological feature of excess rather than increased intraepithelial lymphocytes, though both share similar clinical presentations and risk factors. Diagnosis requires with multiple biopsies from the colon, as the mucosa appears normal endoscopically, and histopathological confirmation of the thickened band is essential. Management focuses on symptom relief and addressing triggers, starting with discontinuation of offending medications and lifestyle modifications like ; first-line pharmacological treatment is (9 mg daily for 6-8 weeks), which induces remission in most patients, though relapses may occur upon tapering. Adjunctive therapies include antidiarrheals such as , bile acid binders like cholestyramine, or , with surgery reserved for rare refractory cases. generally has a benign course with good response to treatment, affecting an estimated 700,000 people in the United States.

Overview

Definition and Classification

Collagenous colitis is a chronic affecting the colon, primarily characterized by the deposition of a thickened subepithelial band exceeding 10 μm in thickness within the , which leads to persistent watery, non-bloody in the absence of visible mucosal abnormalities on . This histological hallmark distinguishes it from other forms of , as the colon appears endoscopically normal or near-normal, with diagnosis relying on findings. It is classified as one of the two primary subtypes of , alongside lymphocytic colitis, both of which fall under the broader category of inflammatory bowel diseases but are differentiated from and by their lack of macroscopic lesions, preserved crypt architecture, and specific microscopic features. as a group is defined by chronic with normal or minimally altered endoscopic appearances, but collagenous colitis specifically requires the pathognomonic collagen band for diagnosis, often accompanied by intraepithelial and lamina propria . The condition was first described in 1976 by Swedish pathologist Carl-Göran Lindström, who reported a case of chronic watery in a middle-aged woman with a distinctive layer in colonic biopsies, coining the term to highlight this unique accumulation. The nomenclature derives from "," denoting inflammation of the colon, and "," referring to the abnormal deposition that forms the diagnostic collagen band.

Pathophysiology

Collagenous colitis is characterized by a distinctive histological abnormality in the colonic mucosa, featuring a thickened subepithelial band exceeding 10 μm in thickness, primarily due to excessive deposition of type VI. This band, often irregular and trapping entrapped capillaries and inflammatory cells, contrasts with the normal subepithelial layer, which measures less than 3 μm. Accompanying this fibrotic change is an increased number of intraepithelial lymphocytes, typically exceeding 20 per 100 surface epithelial cells, alongside a mixed inflammatory infiltrate in the . These features indicate a chronic inflammatory process confined to the superficial mucosa without deeper glandular involvement. The underlying immunological mechanisms involve a dysregulated Th1/Th17-mediated , with infiltration of + T cells into the and , leading to the release of pro-inflammatory cytokines such as TNF-α and IL-17. Pro-inflammatory cytokines such as TNF-α and IFN-γ contribute to epithelial barrier dysfunction by downregulating proteins like claudins 4, 5, and 8, thereby increasing mucosal permeability to luminal antigens and , which perpetuates the inflammatory cycle. Recent single-cell transcriptomic analyses have identified expansion of cytotoxic + T cells, including tissue-resident memory subsets, contributing to the inflammatory profile. This immune activation is thought to be triggered by luminal factors, including bile acids, which may exacerbate epithelial injury and promote . Fibroblasts play a central role in the through abnormal activation, resulting in dysregulated remodeling and overproduction of . This process is driven by elevated expression of transforming growth factor-β1 (TGF-β1), which stimulates differentiation and fibrogenesis, leading to persistent accumulation. Impaired degradation further contributes, associated with polymorphisms in (MMP) genes, such as MMP-9, which reduce enzymatic activity and favor net matrix deposition. Autoimmune mechanisms may contribute to this fibroinflammatory response, though their precise role remains under investigation.

Clinical Features

Signs and Symptoms

Collagenous colitis primarily presents with chronic watery, non-bloody lasting more than 4 weeks, characterized by a of 6 stools per day (range 1-23), with 66% of patients reporting 4-9 stools daily and 22% experiencing 10 or more. Nocturnal occurs in 27% of cases, contributing to sleep disruption and overall symptom burden. This is typically secretory in nature, without blood or mucus, and distinguishes the condition from inflammatory bowel diseases like . Accompanying symptoms include abdominal cramping or pain in 41% of patients, weight loss in 42% (with a median loss of 6 kg and range 3-20 kg), and . Additional common features encompass , , fecal urgency, and incontinence, which exacerbate discomfort and limit daily activities. These manifestations often lead to if unmanaged, though fever and rectal bleeding are notably absent, helping differentiate it from infectious or . The frequent significantly impairs , with patient surveys indicating reduced physical functioning, social participation, and emotional well-being during active disease, comparable to impairments seen in other chronic diarrheal conditions. In rare cases, patients may experience only mild fecal urgency without overt , though this is less typical and still warrants evaluation. Collagenous colitis is sometimes associated with autoimmune conditions such as celiac disease.

Complications

Collagenous colitis, characterized by persistent watery diarrhea, commonly leads to and imbalances, such as and , due to fluid and electrolyte loss over time. These imbalances can manifest as , , and , particularly in elderly patients or those with prolonged symptoms, necessitating prompt fluid replacement to prevent severe morbidity. Unintended , reported in 42% of cases, and can occur due to chronic and , with rare instances of malabsorption (such as ) or contributing to and nutritional deficiencies. This can exacerbate overall debility and reduce if the underlying is not managed effectively. Rare but serious complications include , an acute dilation of the colon with systemic toxicity, which has been documented in isolated case reports despite the generally benign course of the disease. Colonic perforation, either spontaneous or following , occurs in fewer than 1% of cases and is often linked to friable mucosa or procedural trauma, with most instances resolving through conservative management such as antibiotics and bowel rest. Extraintestinal manifestations, such as , , or skin lesions like , may also arise, potentially reflecting an underlying immune-mediated process. Regarding long-term risks, chronic inflammation in collagenous colitis does not appear to elevate the risk of compared to the general population, as evidenced by cohort studies showing no increased incidence over follow-up periods of up to 12 years. While neoplastic disorders have been reported coincidentally, the evidence for a causal link remains weak.

and Risk Factors

Causes and Pathogenesis

The etiology of collagenous colitis (CC) remains multifactorial and incompletely understood, with autoimmune dysregulation emerging as a primary suspected mechanism. Up to 47% of patients with CC report concomitant autoimmune diseases, significantly higher than in the general population. Strong associations exist with celiac disease, observed in approximately 5-12% of CC cases, as well as autoimmune thyroiditis (prevalence around 12-17%, odds ratio 2.3) and . These comorbidities suggest an underlying immune-mediated predisposition, potentially involving genetic factors such as HLA associations shared with other autoimmune conditions. Drug-induced triggers play a prominent role, with chronic use of certain medications increasing CC risk through disruption of the mucosal barrier. Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with an elevated of 2-4 for developing CC, while proton pump inhibitors (PPIs, such as ) confer even higher risk ( up to 3.4), and statins and selective serotonin reuptake inhibitors (SSRIs) show similar associations ( approximately 2). The proposed mechanism involves NSAID- and PPI-mediated impairment of epithelial integrity, increased paracellular permeability, and potential , allowing luminal antigens to provoke aberrant immune responses. Discontinuation of these drugs often leads to resolution, supporting a causal link. Additional risk factors include lifestyle and physiological elements. Current doubles to triples the risk of CC (odds ratio 2-3), with higher rates among younger patients. Alcohol consumption is linked to increased odds (approximately 1.6), potentially exacerbating mucosal . Emerging evidence points to microbial dysbiosis, with alterations resembling those in , and , which may contribute to and chronicity in a subset of cases. The pathogenic model posits that luminal antigens, toxins, or microbial factors initiate a T-cell mediated in genetically susceptible individuals, culminating in chronic subepithelial inflammation and collagen deposition. No single causative agent has been identified, but interactions among triggers—such as barrier disruption from drugs or —likely amplify this process, leading to without overt mucosal ulceration.

Epidemiology

Collagenous colitis predominantly affects females, with reported female-to-male ratios ranging from 3:1 to 8:1 across studies, and exhibits a peak incidence in the sixth decade of life, typically between ages 60 and 70 years. The condition is rare in children, with most cases diagnosed in adults and median ages at diagnosis around 65-67 years. Incidence rates for collagenous colitis have been reported at 9.9 per 100,000 person-years in the United States (, 2011-2019) and approximately 12.2 per 100,000 person-years in during similar periods. Trends show stability after a peak of 19.6 per 100,000 in 2011, attributed to improved diagnostic awareness rather than true increases in disease occurrence.01060-9/fulltext) Prevalence estimates reach up to 116.7 per 100,000 in , reflecting rising recognition due to enhanced practices and histopathological examination. In , prevalence is around 100.1 per 100,000 as of 2019. Geographic variation indicates higher rates in and compared to other regions, with a 2021 Olmsted County study confirming female predominance at a 4.7:1 ratio and associations with HLA alleles such as HLA-B08:01, HLA-DRB103:01, and HLA-DQB1*02:01, which are shared with other immune-mediated diseases like celiac disease and . In cohort studies, smoking and proton pump inhibitor (PPI) use account for 20-30% of attributable risk, with current conferring a hazard ratio of 3.68 and PPI use a hazard ratio of 1.59 for developing collagenous colitis.

Diagnosis

Clinical Evaluation

The clinical evaluation of collagenous colitis begins with a detailed history taking to identify characteristic features and potential triggers. Patients typically present with chronic watery, non-bloody diarrhea lasting more than four weeks, often accompanied by urgency and nocturnal stools. A thorough medication history is essential, as nonsteroidal anti-inflammatory drugs (NSAIDs) and are commonly associated with disease onset or exacerbation. status should be assessed, given its role as a for earlier onset and increased severity. Additionally, recent , antibiotic use, or exposure to potential pathogens must be explored to exclude infectious etiologies through subsequent stool testing. Physical examination is usually unremarkable in collagenous colitis, reflecting the absence of gross mucosal abnormalities. However, signs of , such as dry mucous membranes or , may be evident in cases of severe or prolonged . Mild abdominal tenderness can occur, particularly if cramping is present, though systemic signs like fever are rare. Differential diagnosis is critical to distinguish collagenous colitis from other causes of chronic diarrhea, guiding further testing. (IBS) is a common consideration but lacks inflammatory markers and is diagnosed by exclusion after normal . Celiac disease should be ruled out via serologic testing for tissue transglutaminase antibodies, especially given symptom overlap. Infectious colitis requires stool studies for pathogens like Clostridium difficile or parasites, while (IBD) is differentiated through endoscopic findings and . Initial laboratory evaluation supports the assessment by identifying complications or alternative causes. A (CBC) is typically normal, with being rare unless chronic blood loss occurs. panels help detect imbalances from , such as . Inflammatory markers like (CRP) or (ESR) show only mild elevation in a subset of patients. Fecal calprotectin is elevated in 50 to 70 percent of cases, indicating low-grade inflammation and aiding in distinguishing from noninflammatory conditions like IBS. are recommended to exclude as a contributing factor.

Histological Diagnosis

The histological diagnosis of collagenous colitis relies on endoscopic evaluation followed by histopathological examination of colonic biopsies, as the condition is characterized by normal or near-normal macroscopic appearance during . typically reveals a normal-appearing mucosa or only subtle findings such as mild or nodularity, necessitating multiple random biopsies from both the right and left colon for adequate diagnostic yield. Guidelines recommend obtaining at least four to eight biopsies, with a minimum of two from the and two from the , to achieve a diagnostic sensitivity exceeding 90% in cases of clinical suspicion. Biopsies should be taken from both normal-appearing and any subtly abnormal mucosa to maximize detection, as focal involvement can occur. Definitive histopathological criteria for collagenous colitis include a thickened subepithelial collagen band measuring 10 μm or greater in thickness, best visualized and confirmed using , alongside an increased number of intraepithelial lymphocytes exceeding 20 per 100 surface epithelial cells on hematoxylin and eosin-stained sections. Additional features encompass surface epithelial damage, such as flattening or cuboidal changes, and mixed inflammation in the dominated by plasma cells and . These criteria, established in European consensus guidelines, distinguish collagenous colitis from normal colonic mucosa, where the subepithelial layer is typically less than 5 μm thick. Diagnostic challenges arise in differentiating collagenous colitis from lymphocytic colitis, which shares increased intraepithelial lymphocytes but lacks the thickened collagen band, and from normal variants or early disease where the collagen deposition may be patchy or borderline. Interobserver variability in histologic interpretation has been reported, but agreement is high (kappa value of 0.90) when using standardized diagnostic categories, as demonstrated in multicenter studies evaluating versus non-microscopic colitis cases. Recent updates in 2024 literature and guidelines reinforce the importance of biopsying normal-appearing mucosa during to avoid missing the , particularly in patients with chronic watery and negative stool studies.

Management

Treatment

The primary treatment for collagenous colitis is , a with high topical activity and low systemic , administered orally at 9 mg/day for 6-8 weeks as first-line therapy, achieving clinical remission in approximately 80-90% of patients. For maintenance to prevent relapses, which occur in about 50-60% of cases post-induction, is tapered to 6 mg/day, sustaining remission in up to 84% of patients over a of 39 weeks. In cases of distal colonic involvement or intolerance to oral formulations, topical enemas (2 mg/100 mL) offer an effective alternative for inducing remission with minimal systemic effects. For patients with mild symptoms or those unresponsive to , second-line options include symptomatic relief with antidiarrheals such as , which provides response rates of around 62% in mild cases by reducing stool frequency. binders like cholestyramine are useful for malabsorption-associated , yielding approximately 60% response rates. Mesalamine, an , shows mixed efficacy with response rates of 50-70% in some cohorts, though placebo-controlled trials indicate it is inferior to for short-term induction. In refractory cases, where symptoms persist despite , immunomodulators such as (thiopurines) are considered, achieving response in about 49% of patients. Biologics including and demonstrate higher efficacy, with up to 73% response rates in budesonide failures by targeting gut-specific inflammation. Emerging (JAK) inhibitors like have shown promise in steroid-refractory disease, with 2025 case reports documenting complete symptom resolution and mucosal healing in patients with long-standing collagenous colitis. For rare cases unresponsive to medical therapy, surgical options such as may be considered as a last resort. Lifestyle modifications play a supportive role, including smoking cessation to reduce relapse risk and discontinuation of potential triggers such as proton pump inhibitors (PPIs) or nonsteroidal anti-inflammatory drugs (NSAIDs). Dietary adjustments, such as a or gluten-free regimen in cases of celiac disease overlap, can alleviate symptoms by minimizing irritants and improving stool consistency. Recent 2024 guidelines from major societies emphasize as the cornerstone of therapy due to its superior efficacy over alternatives. Pilot studies on (e.g., and strains) and extract suggest potential for maintenance therapy with partial remission rates, though larger randomized trials are ongoing to confirm benefits beyond .

Prognosis

Collagenous colitis generally follows a benign, relapsing-remitting course, with most patients experiencing chronic watery that waxes and wanes over time. With as first-line therapy, 77-100% of patients achieve clinical remission within 6-8 weeks, defined as fewer than three stools per day without urgency or incontinence. However, upon discontinuation of treatment, occurs in 40-80% of cases, often within 1-2 years, with a median time to relapse of about 39 days. Factors influencing prognosis include the timeliness of diagnosis and treatment initiation, which can shorten symptom duration and enhance remission durability, as delays may exacerbate dehydration and nutritional deficits. Refractory disease, affecting 10-20% of patients who do not respond to budesonide, is frequently linked to persistent exposure to inciting agents like nonsteroidal anti-inflammatory drugs (NSAIDs) or proton pump inhibitors (PPIs), or underlying comorbidities such as autoimmune conditions. Maintenance therapy with low-dose budesonide (e.g., 6 mg daily) reduces relapse risk to under 30% compared to 75% with placebo. Mortality in collagenous colitis does not exceed that of the general , and severe morbidity is uncommon, with rare fatalities from complications like colonic reported in isolated case series at rates below 0.1%. The majority of patients enjoy a normal life expectancy with appropriate . Long-term follow-up emphasizes symptom tracking and fecal calprotectin measurement, though the latter's utility is limited as levels may remain normal in up to half of active cases. In 2025, the validated Score (MCS), derived from patient-reported outcomes, emerged as a tool to quantify symptom severity and remission status, improving assessment of disease control. Cohort studies spanning up to 10 years demonstrate sustained clinical remission in approximately 50-67% of patients receiving maintenance therapy, underscoring the value of ongoing .

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK541100/
  2. https://www.mayoclinic.org/diseases-conditions/microscopic-colitis/symptoms-causes/syc-20351478
  3. https://www.niddk.nih.gov/health-information/digestive-diseases/microscopic-colitis/definition-facts
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC10342440/
  5. https://onlinelibrary.wiley.com/doi/10.1177/2050640620951905
  6. https://pubmed.ncbi.nlm.nih.gov/934705/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC10652163/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC1866842/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC5064027/
  10. https://www.nature.com/articles/s41467-025-59648-8
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC5717882/
  12. https://pubmed.ncbi.nlm.nih.gov/21305678/
  13. https://pubmed.ncbi.nlm.nih.gov/9038667/
  14. https://www.mayoclinicproceedings.org/article/S0025-6196(21)00246-9/fulltext
  15. https://pubmed.ncbi.nlm.nih.gov/20638918/
  16. https://elifesciences.org/articles/79397
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3441171/
  18. https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/collagenous-colitis-and-lymphocytic-colitis
  19. https://pubmed.ncbi.nlm.nih.gov/18584272/
  20. https://www.tandfonline.com/doi/full/10.2147/CEG.S67233
  21. https://pubmed.ncbi.nlm.nih.gov/10028448/
  22. https://journals.lww.com/eurojgh/fulltext/2017/05000/family_history%2C_comorbidity%2C_smoking_and_other.15.aspx
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC9062845/
  24. https://academic.oup.com/jcem/article/110/11/e3730/8052064
  25. https://www.gastrojournal.org/article/S0016-5085%2820%2930584-9/abstract
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC9338644/
  27. https://www.jwatch.org/na40920/2016/03/29/are-ppis-nsaids-and-ssris-associated-with-microscopic
  28. https://pubmed.ncbi.nlm.nih.gov/26956016/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC1774864/
  30. https://pubmed.ncbi.nlm.nih.gov/21854096/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC9340522/
  32. https://journals.lww.com/ctg/fulltext/2019/07000/the_gut_microbiota_in_collagenous_colitis_shares.11.aspx
  33. https://pubmed.ncbi.nlm.nih.gov/11680602/
  34. https://www.cghjournal.org/article/S1542-3565(21)00691-1/fulltext
  35. https://pubmed.ncbi.nlm.nih.gov/32502240/
  36. https://www.gastrojournal.org/article/S0016-5085(20)30584-9/fulltext
  37. https://pubmed.ncbi.nlm.nih.gov/32371109/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC6018687/
  39. https://www.uptodate.com/contents/microscopic-lymphocytic-and-collagenous-colitis-clinical-manifestations-diagnosis-and-management
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC3654232/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC10869377/
  42. https://www.ccjm.org/content/91/4/215
  43. https://www.sciencepublishinggroup.com/article/10.11648/j.ajim.20150306.14
  44. https://pubmed.ncbi.nlm.nih.gov/24440672/
  45. https://journals.lww.com/ajg/fulltext/2004/10001/a_randomized_controlled_pilot_study_comparing.812.aspx
  46. https://journals.lww.com/ajg/fulltext/2025/10002/s3778_the_great_pretender__a_case_of.3776.aspx
  47. https://pubmed.ncbi.nlm.nih.gov/40852031/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC4754103/
  49. https://www.mayoclinic.org/diseases-conditions/microscopic-colitis/diagnosis-treatment/drc-20351483
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC6486307/
  51. https://pubmed.ncbi.nlm.nih.gov/17764013/
  52. https://gut.bmj.com/content/65/1/47
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC4528022/
  54. https://www.consultant360.com/articles/collagenous-colitis-patient-chronic-diarrhea-underdiagnosed-and-undertreated-condition
  55. https://pubmed.ncbi.nlm.nih.gov/20464421/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC10444001/
  57. https://academic.oup.com/ecco-jcc/article/19/9/jjaf153/8285000
  58. https://journals.lww.com/ctg/fulltext/2019/09000/long_term_natural_history_of_microscopic_colitis_.2.aspx
Add your contribution
Related Hubs
User Avatar
No comments yet.